Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy
Summary In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD34 + fraction). The a...
Gespeichert in:
| Veröffentlicht in: | British journal of haematology 2015-03, Vol.168 (5), p.689-700 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 700 |
|---|---|
| container_issue | 5 |
| container_start_page | 689 |
| container_title | British journal of haematology |
| container_volume | 168 |
| creator | Romano, Alessandra Parrinello, Nunziatina Laura Vetro, Calogero Forte, Stefano Chiarenza, Annalisa Figuera, Amalia Motta, Giovanna Palumbo, Giuseppe Alberto Ippolito, Massimo Consoli, Ugo Raimondo, Francesco Di |
| description | Summary
In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD34 + fraction). The absolute MDSC count was investigated in 60 consecutive newly diagnosed HL patients and correlated with clinical variables at diagnosis and outcome. Patients received standard‐of‐care chemotherapy with the exception of interim fluorodeoxyglucose positron emission tomography (PET‐2)‐positive patients, who were switched early to a salvage regimen. All MDSC subsets were increased in HL patients compared to normal subjects (P |
| doi_str_mv | 10.1111/bjh.13198 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1653130256</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1653130256</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3608-b576af670743c1d549d3ccafd4dbb67c90e9aba99ddbb205e9113f2da55687633</originalsourceid><addsrcrecordid>eNp1kbFu2zAQhomgQey4HfoCBcdmkE2KIiWNrdHECQxkaWeBIk82E0lUSamGtjxCXiAvlycJHbndyuVA4uN3uPsR-kzJkoazKh_2S8ponp2hOWWCRzFN6Ac0J4SkESVJNkOX3j8QQhnh9ALNYs5SkSVijl7Wxqmhlr1pd7gZobZGvz49a3DmD2jsh65z4L11WEFde6yscxBwwAfT77GqTWuUrLEdemUbwKbFG6t3j6Fux6bb20biLtih7T3uHYSfGg9daFE52_aTRWJn_GN4k1p2R8D3LoC78SM6r2Tt4dOpLtCv6x8_15toe39zu_62jRQTJItKngpZiZSkCVNU8yTXTClZ6USXpUhVTiCXpcxzHe4x4ZBTyqpYS85FlgrGFujr5O2c_T2A74vG-OPAsgU7-IIKzsLuYi4CejWhylnvHVRF50wj3VhQUhzTKEIaxXsagf1y0g5lA_of-Xf9AVhNwMHUMP7fVHy_20zKN6K_m18</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1653130256</pqid></control><display><type>article</type><title>Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Romano, Alessandra ; Parrinello, Nunziatina Laura ; Vetro, Calogero ; Forte, Stefano ; Chiarenza, Annalisa ; Figuera, Amalia ; Motta, Giovanna ; Palumbo, Giuseppe Alberto ; Ippolito, Massimo ; Consoli, Ugo ; Raimondo, Francesco Di</creator><creatorcontrib>Romano, Alessandra ; Parrinello, Nunziatina Laura ; Vetro, Calogero ; Forte, Stefano ; Chiarenza, Annalisa ; Figuera, Amalia ; Motta, Giovanna ; Palumbo, Giuseppe Alberto ; Ippolito, Massimo ; Consoli, Ugo ; Raimondo, Francesco Di</creatorcontrib><description>Summary
In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD34 + fraction). The absolute MDSC count was investigated in 60 consecutive newly diagnosed HL patients and correlated with clinical variables at diagnosis and outcome. Patients received standard‐of‐care chemotherapy with the exception of interim fluorodeoxyglucose positron emission tomography (PET‐2)‐positive patients, who were switched early to a salvage regimen. All MDSC subsets were increased in HL patients compared to normal subjects (P < 0·0001) and were higher in non‐responders. However, a strong prognostic significance was limited to immature (CD34+) MDSC. A cut‐off level of 0·0045 × 109/l for CD34+MDSC resulted in 89% (95% confidence interval [CI] 52–99%) sensitivity and 92% (95% CI 81–98%) specificity. The positive predictive value to predict progression‐free survival was 0·90 for PET‐2 and 0·98 for CD34+MDSC count; the negative predictive value was 0·57 for PET‐2 and 0·73 for CD34+MDSC. PFS was significantly shorter in patients with more than 0·0045 × 109 CD34+MDSC cells/l at diagnosis and/or PET‐2 positivity (P < 0·0001). In conclusion, all circulating MDSC subsets are increased in HL; CD34+MDSC predict short PFS, similarly to PET‐2 but with the advantage of being available at diagnosis.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.13198</identifier><identifier>PMID: 25376846</identifier><language>eng</language><publisher>England</publisher><subject>Adolescent ; Adult ; Aged ; Antigens, CD34 ; Disease-Free Survival ; Female ; Hodgkin Disease - blood ; Hodgkin Disease - diagnostic imaging ; Hodgkin Disease - mortality ; Hodgkin Disease - therapy ; hodgkin lymphoma ; Humans ; Leukocyte Count ; Male ; Middle Aged ; Myeloid Cells ; myeloid‐derived suppressor cells ; positron emission tomography‐2 ; Positron-Emission Tomography ; Prospective Studies ; Radiography ; Survival Rate</subject><ispartof>British journal of haematology, 2015-03, Vol.168 (5), p.689-700</ispartof><rights>2014 John Wiley & Sons Ltd</rights><rights>2014 John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3608-b576af670743c1d549d3ccafd4dbb67c90e9aba99ddbb205e9113f2da55687633</citedby><cites>FETCH-LOGICAL-c3608-b576af670743c1d549d3ccafd4dbb67c90e9aba99ddbb205e9113f2da55687633</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjh.13198$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjh.13198$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25376846$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romano, Alessandra</creatorcontrib><creatorcontrib>Parrinello, Nunziatina Laura</creatorcontrib><creatorcontrib>Vetro, Calogero</creatorcontrib><creatorcontrib>Forte, Stefano</creatorcontrib><creatorcontrib>Chiarenza, Annalisa</creatorcontrib><creatorcontrib>Figuera, Amalia</creatorcontrib><creatorcontrib>Motta, Giovanna</creatorcontrib><creatorcontrib>Palumbo, Giuseppe Alberto</creatorcontrib><creatorcontrib>Ippolito, Massimo</creatorcontrib><creatorcontrib>Consoli, Ugo</creatorcontrib><creatorcontrib>Raimondo, Francesco Di</creatorcontrib><title>Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>Summary
In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD34 + fraction). The absolute MDSC count was investigated in 60 consecutive newly diagnosed HL patients and correlated with clinical variables at diagnosis and outcome. Patients received standard‐of‐care chemotherapy with the exception of interim fluorodeoxyglucose positron emission tomography (PET‐2)‐positive patients, who were switched early to a salvage regimen. All MDSC subsets were increased in HL patients compared to normal subjects (P < 0·0001) and were higher in non‐responders. However, a strong prognostic significance was limited to immature (CD34+) MDSC. A cut‐off level of 0·0045 × 109/l for CD34+MDSC resulted in 89% (95% confidence interval [CI] 52–99%) sensitivity and 92% (95% CI 81–98%) specificity. The positive predictive value to predict progression‐free survival was 0·90 for PET‐2 and 0·98 for CD34+MDSC count; the negative predictive value was 0·57 for PET‐2 and 0·73 for CD34+MDSC. PFS was significantly shorter in patients with more than 0·0045 × 109 CD34+MDSC cells/l at diagnosis and/or PET‐2 positivity (P < 0·0001). In conclusion, all circulating MDSC subsets are increased in HL; CD34+MDSC predict short PFS, similarly to PET‐2 but with the advantage of being available at diagnosis.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens, CD34</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Hodgkin Disease - blood</subject><subject>Hodgkin Disease - diagnostic imaging</subject><subject>Hodgkin Disease - mortality</subject><subject>Hodgkin Disease - therapy</subject><subject>hodgkin lymphoma</subject><subject>Humans</subject><subject>Leukocyte Count</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloid Cells</subject><subject>myeloid‐derived suppressor cells</subject><subject>positron emission tomography‐2</subject><subject>Positron-Emission Tomography</subject><subject>Prospective Studies</subject><subject>Radiography</subject><subject>Survival Rate</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kbFu2zAQhomgQey4HfoCBcdmkE2KIiWNrdHECQxkaWeBIk82E0lUSamGtjxCXiAvlycJHbndyuVA4uN3uPsR-kzJkoazKh_2S8ponp2hOWWCRzFN6Ac0J4SkESVJNkOX3j8QQhnh9ALNYs5SkSVijl7Wxqmhlr1pd7gZobZGvz49a3DmD2jsh65z4L11WEFde6yscxBwwAfT77GqTWuUrLEdemUbwKbFG6t3j6Fux6bb20biLtih7T3uHYSfGg9daFE52_aTRWJn_GN4k1p2R8D3LoC78SM6r2Tt4dOpLtCv6x8_15toe39zu_62jRQTJItKngpZiZSkCVNU8yTXTClZ6USXpUhVTiCXpcxzHe4x4ZBTyqpYS85FlgrGFujr5O2c_T2A74vG-OPAsgU7-IIKzsLuYi4CejWhylnvHVRF50wj3VhQUhzTKEIaxXsagf1y0g5lA_of-Xf9AVhNwMHUMP7fVHy_20zKN6K_m18</recordid><startdate>201503</startdate><enddate>201503</enddate><creator>Romano, Alessandra</creator><creator>Parrinello, Nunziatina Laura</creator><creator>Vetro, Calogero</creator><creator>Forte, Stefano</creator><creator>Chiarenza, Annalisa</creator><creator>Figuera, Amalia</creator><creator>Motta, Giovanna</creator><creator>Palumbo, Giuseppe Alberto</creator><creator>Ippolito, Massimo</creator><creator>Consoli, Ugo</creator><creator>Raimondo, Francesco Di</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201503</creationdate><title>Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy</title><author>Romano, Alessandra ; Parrinello, Nunziatina Laura ; Vetro, Calogero ; Forte, Stefano ; Chiarenza, Annalisa ; Figuera, Amalia ; Motta, Giovanna ; Palumbo, Giuseppe Alberto ; Ippolito, Massimo ; Consoli, Ugo ; Raimondo, Francesco Di</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3608-b576af670743c1d549d3ccafd4dbb67c90e9aba99ddbb205e9113f2da55687633</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens, CD34</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Hodgkin Disease - blood</topic><topic>Hodgkin Disease - diagnostic imaging</topic><topic>Hodgkin Disease - mortality</topic><topic>Hodgkin Disease - therapy</topic><topic>hodgkin lymphoma</topic><topic>Humans</topic><topic>Leukocyte Count</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloid Cells</topic><topic>myeloid‐derived suppressor cells</topic><topic>positron emission tomography‐2</topic><topic>Positron-Emission Tomography</topic><topic>Prospective Studies</topic><topic>Radiography</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romano, Alessandra</creatorcontrib><creatorcontrib>Parrinello, Nunziatina Laura</creatorcontrib><creatorcontrib>Vetro, Calogero</creatorcontrib><creatorcontrib>Forte, Stefano</creatorcontrib><creatorcontrib>Chiarenza, Annalisa</creatorcontrib><creatorcontrib>Figuera, Amalia</creatorcontrib><creatorcontrib>Motta, Giovanna</creatorcontrib><creatorcontrib>Palumbo, Giuseppe Alberto</creatorcontrib><creatorcontrib>Ippolito, Massimo</creatorcontrib><creatorcontrib>Consoli, Ugo</creatorcontrib><creatorcontrib>Raimondo, Francesco Di</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romano, Alessandra</au><au>Parrinello, Nunziatina Laura</au><au>Vetro, Calogero</au><au>Forte, Stefano</au><au>Chiarenza, Annalisa</au><au>Figuera, Amalia</au><au>Motta, Giovanna</au><au>Palumbo, Giuseppe Alberto</au><au>Ippolito, Massimo</au><au>Consoli, Ugo</au><au>Raimondo, Francesco Di</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2015-03</date><risdate>2015</risdate><volume>168</volume><issue>5</issue><spage>689</spage><epage>700</epage><pages>689-700</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>Summary
In the attempt to find a peripheral blood biological marker that could mirror the dysregulated microenvironment of Hodgkin Lymphoma (HL), we analysed the amount of myeloid‐derived suppressor cells (MDSC), including the three main sub‐types (monocytic, granulocytic and CD34 + fraction). The absolute MDSC count was investigated in 60 consecutive newly diagnosed HL patients and correlated with clinical variables at diagnosis and outcome. Patients received standard‐of‐care chemotherapy with the exception of interim fluorodeoxyglucose positron emission tomography (PET‐2)‐positive patients, who were switched early to a salvage regimen. All MDSC subsets were increased in HL patients compared to normal subjects (P < 0·0001) and were higher in non‐responders. However, a strong prognostic significance was limited to immature (CD34+) MDSC. A cut‐off level of 0·0045 × 109/l for CD34+MDSC resulted in 89% (95% confidence interval [CI] 52–99%) sensitivity and 92% (95% CI 81–98%) specificity. The positive predictive value to predict progression‐free survival was 0·90 for PET‐2 and 0·98 for CD34+MDSC count; the negative predictive value was 0·57 for PET‐2 and 0·73 for CD34+MDSC. PFS was significantly shorter in patients with more than 0·0045 × 109 CD34+MDSC cells/l at diagnosis and/or PET‐2 positivity (P < 0·0001). In conclusion, all circulating MDSC subsets are increased in HL; CD34+MDSC predict short PFS, similarly to PET‐2 but with the advantage of being available at diagnosis.</abstract><cop>England</cop><pmid>25376846</pmid><doi>10.1111/bjh.13198</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1048 |
| ispartof | British journal of haematology, 2015-03, Vol.168 (5), p.689-700 |
| issn | 0007-1048 1365-2141 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1653130256 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adolescent Adult Aged Antigens, CD34 Disease-Free Survival Female Hodgkin Disease - blood Hodgkin Disease - diagnostic imaging Hodgkin Disease - mortality Hodgkin Disease - therapy hodgkin lymphoma Humans Leukocyte Count Male Middle Aged Myeloid Cells myeloid‐derived suppressor cells positron emission tomography‐2 Positron-Emission Tomography Prospective Studies Radiography Survival Rate |
| title | Circulating myeloid‐derived suppressor cells correlate with clinical outcome in Hodgkin Lymphoma patients treated up‐front with a risk‐adapted strategy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T15%3A39%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20myeloid%E2%80%90derived%20suppressor%20cells%20correlate%20with%20clinical%20outcome%20in%20Hodgkin%20Lymphoma%20patients%20treated%20up%E2%80%90front%20with%20a%20risk%E2%80%90adapted%20strategy&rft.jtitle=British%20journal%20of%20haematology&rft.au=Romano,%20Alessandra&rft.date=2015-03&rft.volume=168&rft.issue=5&rft.spage=689&rft.epage=700&rft.pages=689-700&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.13198&rft_dat=%3Cproquest_cross%3E1653130256%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1653130256&rft_id=info:pmid/25376846&rfr_iscdi=true |